Company research
Aldeyra Therapeutics, Inc.
CIK 1341235Updated Sep 27, 2026
SecurityALDX · NASDAQ · equity
Name history
Aldexa Therapeutics, Inc. · through Mar 4, 2014Neuron Systems Inc · through Aug 1, 2008
ALDX price & chart
Loading TradingView…
NASDAQ:ALDX on TradingView ↗About the company
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-248, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal
In the news
Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX ↗
Recent filings
10-Q filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Other Events
Items 8.01
4 filing
4 filing
Show 5 more recent filings
4 filing
3 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders · Regulation FD Disclosure
Items 5.02, 5.07, 7.01, 9.01
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 72,059,317Source | 104,606,694Source | 148,326,911Source | 181,291,657Source |
| Property, Plant and Equipment, NetUSD | — | 0Source | 5,764Source | 19,279Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 70,041,254Source | 54,527,092Source | — | 144,419,364Source |
| Assets, CurrentUSD | 71,783,456Source | 104,072,478Source | 147,810,333Source | 181,023,113Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,742,202Source | 2,921,206Source | 4,987,317Source | 6,722,229Source |
| Operating Lease, Right-of-Use AssetUSD | 275,861Source | 266,955Source | 510,814Source | 249,265Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 27,808,927Source | 33,601,823Source | 28,531,881Source | 30,283,628Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 60,163Source | 59,648Source | 59,196Source | 58,560Source |
| Retained Earnings (Accumulated Deficit)USD | -483,957,253Source | -450,110,592Source | -394,259,148Source | -356,716,638Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 0Source | 37,442Source | 0Source | -103,938Source |
| Stockholders' Equity Attributable to ParentUSD | 44,250,390Source | 71,004,871Source | 119,795,030Source | 151,008,029Source |
| Additional Paid in Capital, Common StockUSD | 528,147,480Source | 521,018,373Source | 513,994,982Source | 507,770,045Source |
| Liabilities and EquityUSD | 72,059,317Source | 104,606,694Source | 148,326,911Source | 181,291,657Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 27,808,927Source | 18,601,823Source | 22,260,250Source | 15,360,538Source |
| Operating Lease, Liability, CurrentUSD | 280,537Source | 271,631Source | 239,183Source | 249,265Source |
| Accounts Payable, CurrentUSD | 158,461Source | 180,453Source | 1,338,057Source | 133,625Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 0Source | 271,631Source | 0Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 6,120,297Source | 12,118,367Source | 5,536,464Source | 14,065,885Source |
| Deferred Revenue, CurrentUSD | 6,000,000Source | 6,000,000Source | — | — |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 15,249,632Source | 31,372Source | 15,146,546Source | 911,763Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 0Source | 15,000,000Source | 0Source | 14,923,090Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -33,846,661Source | -55,851,444Source | -37,542,510Source | -62,024,636Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,091,413Source | 7,973,499Source | 5,752,771Source | 8,288,976Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -21,992Source | -1,157,604Source | 1,204,432Source | -886,077Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -33,345,682Source | -43,208,747Source | -30,326,128Source | -56,637,187Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 47,736,288Source | -44,915,755Source | 30,000,000Source | -29,954,530Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | 0Source | 16,317Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | 0Source | 532,951Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 1,123,556Source | -171,422Source | -1,270,220Source | 1,220,092Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 15,514,162Source | -88,295,924Source | -1,596,348Source | -85,371,625Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 70,041,254Source | 54,527,092Source | 142,823,016Source | 144,419,364Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,688,125Source | 1,753,792Source | 1,702,188Source | 1,338,542Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 6,091,413Source | 7,973,499Source | 5,752,771Source | 8,288,976Source |
| DepreciationUSD | 251,993Source | 249,623Source | 262,780Source | 258,707Source |
| General and Administrative ExpenseUSD | 9,602,351Source | 11,892,239Source | 13,335,364Source | 15,373,921Source |
| Income Tax Expense (Benefit)USD | 0Source | 1,000Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 1,905,310Source | 1,926,241Source | — | — |
| Investment Income, InterestUSD | 3,323,855Source | 6,191,829Source | 7,323,008Source | 2,349,449Source |
| Marketable Securities, Unrealized Gain (Loss)USD | -100,000Source | 100,000Source | 100,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -33,846,661Source | -55,851,444Source | -37,542,510Source | -62,024,636Source |
| Nonoperating Income (Expense)USD | 1,418,545Source | 4,265,588Source | 5,251,573Source | 655,351Source |
| Operating Lease, ExpenseUSD | 300,000Source | 300,000Source | 300,000Source | 200,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | 1,103,940Source | 350,279Source | 194,129Source | 1,123,427Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -35,265,206Source | -60,117,032Source | -42,794,083Source | -62,679,987Source |
| Income Tax Expense (Benefit)USD | 0Source | 1,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -33,846,661Source | -55,851,444Source | -37,542,510Source | -62,024,636Source |
| Earnings Per Share, BasicUSD per share | -0.56Source | -0.94Source | -0.64Source | -1.06Source |
| Earnings Per Share, DilutedUSD per share | -0.56Source | -0.94Source | -0.64Source | -1.06Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 60,056,557Source | 59,484,794Source | 58,943,205Source | 58,405,897Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 60,056,557Source | 59,484,794Source | 58,943,205Source | 58,405,897Source |
| Interest Expense (non-operating)USD | 1,905,310Source | 1,926,241Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 9,602,351Source | 11,892,239Source | 13,335,364Source | 15,373,921Source |
| Income (Loss) Attributable to Parent, before TaxUSD | 33,846,661Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 33,846,661Source | — | — | — |
| Interest ExpenseUSD | — | — | 2,071,435Source | 1,694,098Source |
| Investment Income, InterestUSD | 3,323,855Source | 6,191,829Source | 7,323,008Source | 2,349,449Source |
| Nonoperating Income (Expense)USD | 1,418,545Source | 4,265,588Source | 5,251,573Source | 655,351Source |
| Operating Lease, ExpenseUSD | 300,000Source | 300,000Source | 300,000Source | 200,000Source |
| Research and Development ExpenseUSD | 25,662,855Source | 48,224,793Source | 29,458,719Source | 47,306,066Source |
Filing attachments
aldx-ex99_1.htm · 8-K · 2026-06-10
EX-99.1 2 aldx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors Lexington, Mass., June 9, 2026 - Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced the appointment of Darlene Deptula-Hicks to Aldeyra’s board of directors (the Board). “Ms. Deptula-Hicks brings decades of experience …
Read attachment ↗aldx-ex99_1.htm · 8-K · 2026-05-01
EX-99.1 2 aldx-ex99_1.htm EX-99.1 Innovative Therapeutics for Immune-Mediated Diseases CORPORATE OVERVIEW May 2026 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2026 Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of o…
Read attachment ↗aldx-ex99_1.htm · 8-K · 2026-03-17
EX-99.1 2 aldx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease Lexington, Mass., March 17, 2026 - Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt of…
Read attachment ↗aldx-ex99_1.htm · 8-K · 2025-12-16
EX-99.1 2 aldx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 News Release Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease Lexington, Mass. December 15, 2025 - Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the…
Read attachment ↗aldx-ex99_1.htm · 8-K · 2025-11-13
EX-99.1 2 aldx-ex99_1.htm EX-99.1 2025 Research & Development Webcast CORPORATE OVERVIEW November 13, 2025 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2025 Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of operation…
Read attachment ↗aldx-ex99_2.htm · 8-K · 2025-11-13
EX-99.2 3 aldx-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 News Release Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast Lexington, Mass. November 13, 2025 - Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at a research and dev…
Read attachment ↗